Free Research Reports on CHLN, MHR, MVIS and NVGN Issued by the Bedford Report
Read Full Article • Fri, Apr 05, 5:09am
Which other executives work with
Philip Johnston? Click to meet them now.
SEC Center Application
Just Released!
LAST UPDATED: 10/13/2012, 12:27 PM EDT
Philip A Johnston , Non-executive Director since 1997, Mr Johnston was elected Chairman of Novogen Limited with effect from January 2001. Mr Johnston has extensive experience in the pharmaceutical industry including 9 years as an Executive Director of Wellcome Australia Limited. He was previously a Director of two subsidiary Companies of GlaxoWellcome. He has had responsibility for production, distribution, quality assurance and consumer product development and has been directly involved in the establishment of strategic alliances and joint ventures. He has completed a number of executive development programs including the University of NSW and the London Business School. During the last three years Mr Johnston has served as a Director of the ASX listed company, Lipa Pharmaceuticals Limited and is currently a Director of NASDAQ listed, Novogen subsidiary, Marshall Edwards, Inc. Mr Johnston's directorship of Lipa ceased in November 2007 following a scheme of arrangement which saw Lipa ceasing as a public company at that time. Mr PA Johnston (Chairman) - resigned as Chairman and Director 18 October, 2010.
PassFail added 3 new financial items to our total of over 8 Videos, Articles, Blogs, & Podcasts on Novogen Ltd.. We update our news every 15 minutes from over 24,479 sources. We are finance.
Read Full Article • Fri, Apr 05, 5:09am
Read Full Article • Thu, Apr 04, 1:29pm
Read Full Article • Wed, Apr 03, 1:10pm
Read Full Article • Mon, Mar 25, 1:23pm
Read Full Article • Thu, Feb 21, 2:27am
Read Full Article • Wed, Feb 20, 5:15am
Read Full Article • Tue, Feb 19, 11:30am
Read Full Article • Wed, Jan 02, 7:02am
Philip A Johnston , Non-executive Director since 1997, Mr Johnston was elected Chairman of Novogen Limited with effect from January 2001. Mr Johnston has extensive experience in the pharmaceutical industry including 9 years as an Executive Director of Wellcome Australia Limited. He was previously a Director of two subsidiary Companies of GlaxoWellcome. He has had responsibility for production, distribution, quality assurance and consumer product development and has been directly involved in the establishment of strategic alliances and joint ventures. He has completed a number of executive development programs including the University of NSW and the London Business School. During the last three years Mr Johnston has served as a Director of the ASX listed company, Lipa Pharmaceuticals Limited and is currently a Director of NASDAQ listed, Novogen subsidiary, Marshall Edwards, Inc. Mr Johnston's directorship of Lipa ceased in November 2007 following a scheme of arrangement which saw Lipa ceasing as a public company at that time. Mr PA Johnston (Chairman) - resigned as Chairman and Director 18 October, 2010.
